HCLS Review Asia-Pacific Data by Country is an extensive compilation of the latest country-specific data on economies, healthcare, pharmaceutical industries, and R&D in some of the region’s most dynamic markets. This new 38-page report contains data from Australia, Hong Kong SAR, Japan, PR China, South Korea, and Taiwan and is an invaluable resource for anyone looking for up-to-date statistics and trends on these key geographies.
Asia-Pacific is rapidly developing and extremely diverse, spanning both countries at the cutting-edge of innovation and technology as well as emerging economies. According to the Business Research Company, the territory’s pharmaceutical market stands to grow to USD 277 billion by 2021, up from USD 200 billion in 2017, and is the world’s third-largest behind only those of Europe and North America.
Healthcare systems and apparatus in Asia have hit the headlines in recent months thanks to their comparatively competent handling of the COVID-19 pandemic. This, coupled with positive business winds, including an uptick in the number of biotech companies choosing to IPO in the continent, shows the true dynamism of the region and signals its increasing global significance.